These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 38166943

  • 1. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
    Shiari R, Khalili M, Zeinali V, Shashaani N, Samami M, Moghaddamemami FH.
    Pediatr Rheumatol Online J; 2024 Jan 02; 22(1):2. PubMed ID: 38166943
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
    Walling HW, Gerami P, Sontheimer RD.
    Paediatr Drugs; 2010 Jan 02; 12(1):23-34. PubMed ID: 20034339
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
    Marco Puche A, Calvo Penades I, Lopez Montesinos B.
    Clin Exp Rheumatol; 2010 Jan 02; 28(1):135-40. PubMed ID: 20346254
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
    Tayfur AC, Topaloglu R, Gulhan B, Bilginer Y.
    Mod Rheumatol; 2015 Jul 02; 25(4):615-20. PubMed ID: 25800510
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effects of infliximab in treating idiopathic inflammatory myopathies: A review article.
    Ge Y, Li S, Chen F, He L, Li C, Lu X, Wang G.
    Dermatol Ther; 2021 Jul 02; 34(4):e14976. PubMed ID: 33991036
    [Abstract] [Full Text] [Related]

  • 11. [A case of juvenile dermatomyositis with calcinosis universalis--remarkable improvement with aluminum hydroxide therapy].
    Aihara Y, Mori M, Ibe M, Kuriyama T, Takahashi Y, Shimizu C, Shike H, Mitsuda T, Yokota S.
    Ryumachi; 1994 Oct 02; 34(5):879-84. PubMed ID: 7801200
    [Abstract] [Full Text] [Related]

  • 12. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
    Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
    Curr Rheumatol Rep; 2014 Dec 02; 16(12):467. PubMed ID: 25366934
    [Abstract] [Full Text] [Related]

  • 13. Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil.
    Çakan M, Karadağ ŞG, Ayaz NA.
    Turk J Pediatr; 2019 Dec 02; 61(5):771-775. PubMed ID: 32105011
    [Abstract] [Full Text] [Related]

  • 14. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
    Marhaug G, Shah V, Shroff R, Varsani H, Wedderburn LR, Pilkington CA, Brogan PA.
    Rheumatology (Oxford); 2008 Jul 02; 47(7):1031-7. PubMed ID: 18448482
    [Abstract] [Full Text] [Related]

  • 15. [Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].
    Zhou QF, Luo Y, He TY, Ling JY, Xu YB, Yang J, Xia Y.
    Zhonghua Er Ke Za Zhi; 2023 Jun 02; 61(6):538-542. PubMed ID: 37312466
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for developing calcinosis in juvenile dermatomyositis: subcutaneous and myofascial edema in initial magnetic resonance imaging.
    Yi BY, Marrs J, Acharya P, Sura A, Cidon M.
    Rheumatol Int; 2024 Nov 02; 44(11):2577-2582. PubMed ID: 37432516
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
    Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K.
    J Rheumatol; 2006 Aug 02; 33(8):1691-3. PubMed ID: 16881125
    [Abstract] [Full Text] [Related]

  • 18. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
    Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA.
    J Rheumatol; 2005 Sep 02; 32(9):1837-9. PubMed ID: 16142885
    [Abstract] [Full Text] [Related]

  • 19. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis.
    Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, Acar B, Bakkaloğlu SA.
    Int J Rheum Dis; 2023 Aug 02; 26(8):1504-1511. PubMed ID: 37288472
    [Abstract] [Full Text] [Related]

  • 20. Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
    Pavlov-Dolijanovic SR, Vujasinovic Stupar NZ, Gavrilov N, Seric S.
    Rheumatol Int; 2014 Nov 02; 34(11):1615-8. PubMed ID: 24789670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.